Israel’s business newspaper Globes is reporting that KarmelSonix Ltd, a company consisting of Israel’s KarmelSonix and Australia’s Pulmosonix, received FDA approval for the Wheezometer point-of-care wheeze detector. The device records thirty seconds of breathing while applied to the neck area and analyzes and quantifies the wheezing in the audio.
The WheezoMeter™ is calibrated and validated as determined by consensus of a panel of experts who evaluated and scored many recordings for presence of wheeze. The WheezoMeter™ uses a cascade of 6 proprietary technologies to "defend" the signals against false detection of ambient noises as wheeze. Obtain a “spot check” measurement of present wheeze activity, any time, any place, as often as needed without any patient effort. Measure WheezeRATE™ before and after administration of a bronchodilator (“pre-post” test). Communicate status of homebound or remote patient to physician or healthcare professional.
System Components:
WheezoMeter™ with embedded Black Fin® processor. Self-contained cushioned built-in silicone-coated PPG PPG Sensor with broad spectrum frequency response, >60 dB dynamic range and superior ambient noise rejection Allows scrolling of the last 10 measurements for review 2 AA batteries (not included) Infant sensor holder for babies and toddlers (optional)
More from Globes: FDA approves KarmelSonix’s Wheezometer
Product page: Wheezometer
Wheezometer brochure…
